

Special Issue

Multiple Myeloma and Immunology: From Pathophysiology to Therapy

Message from the Guest Editor

Preclinical and clinical research in multiple myeloma has achieved impressive results in recent years. Multiple myeloma onset and development and its microenvironment have been extensively studied, allowing the critical switch from chemotherapy-based approaches to the combination of biological agents and immunotherapies. Following this paradigm shift, outcomes of this still incurable disease have tremendously improved. Indeed, the aim of this issue is to provide a critical overview of the state-of-the-art of immunology preclinical studies and the latest immune-based therapy developments, with a special focus on the new combo treatments and the innovative T cell redirecting therapies.

Guest Editor

Dr. Marco Rossi

1. Hematology Unit, Oncohematology Department, AOU Renato Dulbecco, Catanzaro, Italy
2. Department of experimental and Clinical Medicine, Magna Graecia University, Catanzaro, Italy

Deadline for manuscript submissions

31 July 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/259719

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)